{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007566","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.666397+00:00","generated_at":"2026-06-16T03:45:17.171032+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Bio Q1 WAKIX revenue $119.1M (+40% YoY); GAAP EPS $0.48; patients ~5,200","bullets":["Net product revenue $119.1M, +39.6% YoY; GAAP net income $29.5M ($0.48 diluted EPS) vs $21.5M ($0.35) prior year.","Average patients on WAKIX ~5,100 (+1,200 YoY); exited Q1 with ~5,200 patients.","Cumulative WAKIX net revenue surpassed $1B since launch; Phase 3 IH INTUNE topline data expected Q4 2023.","Non-GAAP adjusted net income $40.1M ($0.66 diluted EPS) vs $31.1M ($0.51) prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007566","json":"https://secwatch.observer/filing/0001558370-23-007566.json","markdown":"https://secwatch.observer/filing/0001558370-23-007566.md","text":"https://secwatch.observer/filing/0001558370-23-007566.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/0001558370-23-007566-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/hrmy-20230502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:45:17.171032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83be17288f770fa2c0f393fa828fc5c9a424ca32","claim":"Harmony Biosciences Holdings, Inc. reported quarter ended March 31, 2023 results: revenue $119.1 million, net income $29.5 million, EPS $0.48.","evidence_excerpt":"--- ‌ Exhibit 99.1 ​ HARMONY BIOSCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue Increased ~40% Year-over-Year to $119.1 Million for First Quarter 2023 ​ Average Number of Patients on WAKIX Increased ~1,200 Year-over-Year to ~5,100 for First Quarter 2023 ​ Exited First Quarter 2023 With ~5,200 Patients on","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/0001558370-23-007566-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$119.1 million"},{"label":"Net income","value":"$29.5 million"},{"label":"EPS","value":"$0.48"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}